Saudi Pharma Giant Expands Regional Presence with Strategic Rebrand
Jamjoom Pharma launches new corporate identity, marking significant expansion across MEA region with strong presence in Egypt. Company reports 17% revenue growth and enhanced regional operations.
Jamjoom Pharma headquarters showcasing new corporate identity and strategic transformation
Major Middle Eastern Pharmaceutical Company Signals Regional Growth
In a significant development highlighting the growing strength of regional pharmaceutical capabilities, Jamjoom Pharma, one of Saudi Arabia's fastest-growing pharmaceutical companies, has unveiled a new corporate identity marking its ambitious expansion across the Middle East and Africa, including enhanced operations in Egypt.
This strategic transformation aligns with Egypt's growing role as a regional economic powerhouse, demonstrating the country's increasing importance in cross-border business partnerships.
Impressive Financial Performance and Market Growth
The company reported remarkable financial results, with revenue growing 17% year-over-year to reach SAR 854 million in the first half of 2025. This growth mirrors the robust economic developments seen across the region, where strategic Gulf investments are driving multiple sectors.
Enhanced Healthcare Access and Innovation
Dr. Tarek Hosni, CEO of Jamjoom Pharma, emphasized the company's commitment to expanding healthcare accessibility: "Our new identity reflects our core mission - serving our patients. We believe everyone deserves access to trusted medicine and the chance to live a better life."
This initiative comes at a crucial time when regional healthcare systems are evolving to meet growing demands, particularly in essential areas such as mental health and general medicine.
Strategic Regional Impact
The company's expansion across 36 countries, with significant operations in Egypt and other key markets, demonstrates the region's growing pharmaceutical manufacturing capabilities and commitment to healthcare advancement. The transformation includes:
- Enhanced manufacturing capacity across 4 regional facilities
- Expansion of product portfolio to 144 active brands
- Focus on key therapeutic areas including ophthalmology and cardiometabolic diseases
- Strengthened regional partnerships and distribution networks
Future Growth Trajectory
With a robust net profit of SAR 289 million and a 34% margin, Jamjoom Pharma's success story represents the growing strength of regional pharmaceutical capabilities and the importance of strategic partnerships in advancing healthcare access across the Middle East and Africa.
Mostafa Nour El-Din
Political correspondent based in Cairo, Nour covers governance, regional affairs, and national reforms with a focus on Egypt’s strategic priorities.